التفاصيل البيبلوغرافية
| العنوان: |
OFF‐THE‐SHELF CD30.CAR‐MODIFIED EPSTEIN‐BARR VIRUS‐SPECIFIC T CELLS (CD30.CAR EBVSTS) PROVIDE A SAFE AND EFFECTIVE THERAPY FOR PATIENTS WITH HODGKIN LYMPHOMA (HL). |
| المؤلفون: |
Ramos, C. A., Quach, D. H., Lulla, P. D., Rouce, R. H., Sharma, S., Ganesh, H. R., Nouraee, N., Briones, Y. D., Becerra‐Dominguez, L., Thakkar, S. G., Mehta, B., Perconti, S., Hsieh, E. M., Zhang, H., Grilley, B. J., Lapteva, N., Brenner, M. K., Heslop, H. E., Rooney, C. M. |
| المصدر: |
Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p83-85, 3p |
| مصطلحات موضوعية: |
HODGKIN'S disease, T cells, STEM cell transplantation |
| مستخلص: |
To prevent graft rejection, we modified the EBVST with a chimeric antigen receptor (CAR) targeting CD30, an antigen that is upregulated on allo-activated T-cells, which will consequently become targets for CD30.CAR EBVST. OFF-THE-SHELF CD30.CAR-MODIFIED EPSTEIN-BARR VIRUS-SPECIFIC T CELLS (CD30.CAR EBVSTS) PROVIDE A SAFE AND EFFECTIVE THERAPY FOR PATIENTS WITH HODGKIN LYMPHOMA (HL) Off-the-shelf allogeneic T-cell therapies face the major challenges of graft-versus-host disease (GVHD) and graft rejection mediated by host and recipient alloreactive T cells, respectively. [Extracted from the article] |
|
Copyright of Hematological Oncology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder